EyeGate's EGP-437 meets Phase III endpoint

EyeGate Pharmaceuticals Inc. (Waltham, Mass.) said transscleral iontophoresis delivery of EGP-437 met the primary endpoint of non-inferiority to standard of care in a 193-patient Phase III trial to tr...